ASXRAD Doses First Patient in Second Cohort of BetaBart (RV-01)
other announcement
Radiopharm Theranostics (RAD) News
Latest articles and price-sensitive announcements with AI sentiment classification.
KalkineRadiopharm Theranostics (ASX:RAD) Gets DSMC Backing to Move RAD202 Into Cohort 4
Highlights Radiopharm has received a positive DSMC recommendation to advance RAD202 into Cohort 4 of the Phase 1 HEAT trial. The trial will now evaluate a higher 180mCi dose in patients with HER2-positive advanced solid tumours. The previous study dose level was 130mCi, announced in April 2026. An earlier diagnostic study in 10 HER2-positive breast cancer patients demonstrated clinical proof-of-concept, positive safety and biodistribution. Radiopharm Theranostics (ASX:RAD) (Nasdaq:RADX) has m...
RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial
other announcement
RAD to meet with US FDA to align on RAD 101 Phase 3 Trial
other announcement
Notice of Extraordinary General Meeting and Proxy Form
other announcement
Clarity (ASX:CU6): What Puts Radiopharmaceutical Clinical Deliv in Focus?
Highlights Clarity is in focus after it released a biotechnology summit presentation in its latest update, creating a current test of evidence-led commercialisation. The Healthcare Stocks backdrop is shaped by clinical progress, regulatory pathways and channel expansion as Australia's market trades near record levels. The central operating question is radiopharmaceutical clinical delivery, with trial milestones, approvals, sales traction and cash use forming the evidence-based scorecard. Aust...
Radiopharm (ASX:RAD) Expands Clinical Momentum with Positive Trial Updates
Highlights RAD 101 met its Phase 2b primary endpoint, with 93% of evaluable patients achieving concordance with MRI imaging in recurrent brain metastases. Radiopharm plans to commence a multi-centre, multi-country Phase 3 registrational trial for RAD 101 in Q4 2026. The first patient in the third dose cohort of the Phase 1 RAD 204 trial achieved a RECIST-confirmed partial response, with tumour shrinkage of up to 43% and progression-free survival exceeding seven months. The company continued adv...
Google NewsRadiopharm Theranostics Applies to Quote 408.8 Million Shares from Tranche 1 Australian Placement - Kalkine
Radiopharm Theranostics Applies to Quote 408.8 Million Shares from Tranche 1 Australian Placement Kalkine
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Radiopharm Theranostics (ASX:RAD) Raises AUD 12.5 Million to Advance Phase 3 Cancer Therapy Program
Highlights Radiopharm has secured firm commitments for an AUD 12.5 million institutional capital raising and launched a SPP targeting up to AUD 6 million. The proceeds will support the Phase 3 registrational study for RAD101, ongoing clinical development across multiple therapeutic programs, and strategic partnering initiatives. Investors have also committed up to AUD 3 million to cover any shortfall under the SPP, subject to shareholder approval. Radiopharm Theranostics (ASX:RAD) (Nasdaq:RA...
Radiopharm Theranostics Secures A$18.5 Million to Propel Phase III-Ready Brain Imaging Agent RAD101
Radiopharm Theranostics Ltd (ASX: RAD), a clinical-stage radiopharmaceutical company specializing in oncology diagnostics and therapeutics, has successfully raised A$18.5 million through a A$12.5 million placement and a fully subscribed A$6.0 million share purchase plan. In July 2026, the company announced that its lead diagnostic candidate, RAD101—a first-in-class PET imaging agent for brain metastases—delivered a positive Phase IIb outcome, with 93% or more of patients meeting the primary ...
Radiopharm Theranostics Secures A$12.5 Million Institutional Funding Ahead of RAD101 Phase 3 Trial Launch
Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX) has successfully raised approximately A$12.5 million in institutional funding, consisting of an A$6.7 million Australian placement and a concurrent US$4.1 million US Direct Registration Offering. The clinical-stage biopharmaceutical firm is also initiating a further A$6 million Share Purchase Plan (SPP) for eligible shareholders. The combined capital raise aims to finance preparations for the RAD101 registrational Phase 3 trial and support...
Radiopharm Theranostics Initiates $10 Million Capital Raise with 800 Million Shares and Options Offering
Radiopharm Theranostics Limited (ASX: RAD) has unveiled a combined capital raising initiative that includes a securities purchase plan and a placement, aiming to secure up to A$10 million. The company plans to issue up to 400 million fully paid ordinary shares under the employee and shareholder purchase plan, along with 200 million options expiring on 31 July 2029 as part of a separate placement. The offer period concludes on 10 September 2026, with new shares anticipated to begin trading on 17 ...
RAD completes A$12.5 M placement and launches A$6 M SPP
capital_raise announcement
Imaging And Radiopharma Names Light Up Health Space
Highlights Medical imaging software and radiopharmaceutical developers have drawn fresh attention this stretch. These niches sit apart from the big exporters, offering a different flavour of health exposure. Global demand for smarter diagnostics and targeted therapies underpins their long-run stories. Not every corner of the health sector marches to the same beat as the giant exporters, and a cluster of specialist names has been quietly commanding attention on the Australian market. Pro Medic...
StockheadHealth Check: Radiopharm goes to the well for $16 million after clinical trial double delight
Radiopharm Theranostics is capitalising on today's two promising cancer imaging trial updates to replenish its coffers via a $16 million ... Read More The post Health Check: Radiopharm goes to the well for $16 million after clinical trial double delight appeared first on Stockhead.
Small CapsRAD Achieves Partial Response in Phase 1 Trial of RAD204
other announcement
RAD Announces Positive Phase 2b Trial Results of RAD 101
other announcement
Radiopharm Theranostics (ASX:RAD) Progresses Pipeline with Multiple Clinical Milestones
Highlights Radiopharm Theranostics is advancing multiple clinical-stage therapeutic and diagnostic programs across oncology indications. Lead candidate RAD204 has completed two Phase I dose cohorts, with tumour uptake confirmed in all treated participants and recruitment underway for the third cohort. RAD202, RAD402 and RV01 continue progressing through Phase I studies. The diagnostic candidate RAD101 reported ~90% concordance with MRI in its Phase 2b study and is prog...
Radiopharm Theranostics (ASX:RAD): Why Are ASX Penny Stocks Facing a Catalyst Test?
Highlights Smaller ASX companies are being judged more closely on funding discipline and meaningful project milestones. Radiopharm Theranostics, Renascor Resources, Botanix Pharmaceuticals, Anson Resources and Dimerix highlight different parts of the sector. Cash runway, execution quality and catalyst delivery are becoming the key themes across the market. ASX penny stocks are facing a sharper c...
Notification regarding unquoted securities - RAD
other announcement
Radiopharm Theranostics (ASX:RAD) Announces Finance and Governance Leadership Changes
Highlights Radiopharm Theranostics will continue its service agreement with Acclime Australia for CFO, financial management, statutory reporting and company secretarial services. Aaron Laurita has been appointed CFO, succeeding Phillip Hains. Amritha Sushil has joined the company as Joint Company Secretary, effective immediately. Nathan Jong will continue serving as Joint Company Secretary alongside Sushil. Radiopharm Theranostics (ASX:RAD) has confirmed the continuation of its service agreem...
Radiopharm Theranostics Draws Attention After Insider Buying
Highlights Radiopharm Theranostics insiders continued accumulating shares despite recent market weakness. The healthcare-focused biotech company remains under close watch amid theranostics sector growth. Investor attention remains centred on insider confidence and clinical development progress. Radiopharm Theranostics continues attracting market attention as insider buying activity and growing interest in precision oncology shape sentiment around the emerging healthcare company. The Australia...
Financial Services and Company Secretary Changes
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Why Is (ASX:RAD) Drawing Attention After Clinical Update?
Highlights Early clinical data signals encouraging tumour targeting Safety profile remains manageable across initial cohort Trial progresses toward higher dosing phase Radiopharm Theranostics has reported early-stage clinical progress, with initial findings pointing to targeted tumour uptake and a stable safety profile, supporting continued development of its investigational therapy. What Is Driving Momentum for (RAD)? Radiopharm Theranostics (ASX:RAD) has entered a significant phase in...
Radiopharm Theranostics (ASX:RAD) to Present Promising Early Data for HER2 Therapy at AACR 2026
Highlights Radiopharm Theranostics will present early clinical data from its HEAT trial at the American Association for Cancer Research Annual Meeting 2026. Initial results from three patients showed tumour uptake of 177Lu-RAD202 at the lowest 30 mCi dose. No dose-limiting toxicities or treatment discontinuations reported. The trial has been cleared to advance to a higher 130 mCi dose cohort following review by the Data Safety and Monitoring Committee. Radiopharm Theranostics Limited (ASX:RAD...
RAD Initial Findings from Phase 1 177Lu-RAD202 Trial
other announcement
Radiopharm (ASX:RAD) Completes Phase 2b Dosing for Brain Metastases Imaging Trial
Highlights Radiopharm Theranostics has completed final patient dosing in the U.S. Phase 2b trial of 18F-RAD101. The study enrolled 30 patients with recurrent brain metastases from various solid tumors. The trial evaluates diagnostic accuracy against MRI with gadolinium. Interim results show 90% concordance with conventional imaging. Clinical trial readout is expected in June 2026. The company plans to transition to a Phase 3 pivotal trial. Radiopharm Theranostics (ASX:RAD) has reached a key m...
RAD Completes Enrollment in Phase 2b Trial of RAD 101
other announcement
Radiopharm Theranostics (ASX:RAD) Advances RAD202 to Higher Dose Level in Phase 1 HEAT Trial
Highlights The DSMC has recommended advancing RAD202 to a 130mCi dose level in the Phase 1 HEAT trial. Radiopharm progresses from Cohort 2 to Cohort 3 in its HER2-positive solid tumour stud. Radiopharm expects to complete Phase 1 dose escalation by the end of 2026. RAD202 targets HER2, a well-established oncology biomarker in multiple solid tumours. Radiopharm Theranostics (ASX:RAD) has received a recommendation from the Data Safety and Monitoring Committee (DSMC) to proceed to the next dose ...
RAD202 Phase 1 HEAT Trial Advances to Dose Level 3
other announcement
Radiopharm (ASX:RAD) Strengthens Clinical Pathway for RAD101 with Siemens Collaboration
Highlights Radiopharm Theranostics has signed a clinical supply agreement with Siemens Healthineers for RAD101 in the U.S. Interim Phase 2b data reported 90% concordance with MRI scans, meeting the primary endpoint. The agreement supports supply for an upcoming global Phase 3 registrational trial. RAD101 demonstrated tumour uptake and improved clarity over equivocal MRI findings. The program holds FDA Fast Track status for diagnosing recurrent brain metastases. Radiopharm Theranostics (ASX:RA...
RAD and Siemens Sign Clinical Supply Agreement for RAD101
other announcement
Change of Director's Interest Notice (IT)
director_dealing announcement
Radiopharm Theranostics (ASX:RAD) Begins First-in-Human Trial of RAD 402 for Advanced Prostate Cancer
Highlights Radiopharm Theranostics has dosed the first patient in its Phase 1 RAD 402 trial for advanced prostate cancer. The therapy targets KLK3 and uses Terbium-161 to enable targeted radiopharmaceutical treatment. The trial will assess safety, tolerability, and early signs of clinical activity through dose escalation. Initial clinical data from the first two dose levels are expected in the second half of 2026. Radiopharm Theranostics (ASX:RAD) has begun clinical evaluation of RAD 402 with...
RAD Doses First Patient in RAD 402 Phase 1 Clinical Study
other announcement
Telix Pharma Gains Traction on Radiopharma Progress
Highlights Clinical updates strengthen pipeline outlook Radiopharma focus drives renewed market attention Financial position supports ongoing expansion Telix Pharmaceuticals is drawing attention as clinical progress and a focused radiopharmaceutical strategy support its long-term positioning in oncology innovation. Telix Advances Radiopharma Strategy Amid Market Focus Telix Pharmaceuticals Ltd (ASX:TLX) has recently attracted market attention as developments within its clinical pipeline...
Radiopharm Theranostics (ASX:RAD) Reports High MRI Concordance in Brain Metastases Imaging Trial
Highlights RAD101 achieved 90% concordance with MRI, meeting the primary endpoint in the Phase 2b trial. PET imaging showed selective uptake in brain metastases, improving detection over MRI alone. Early follow-up data indicates positive trends in sensitivity and specificity for RAD101. The study is on track for final data by June 2026, with FDA Fast Track status supporting development. Radiopharm Theranostics Limited (ASX:RAD) has released new interim findings from its Phase 2b clinical tria...
RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint
other announcement